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Abstract 
Background: The pharmacokinetic parameters after the vaginal or sublingual administration of 
repeated doses of 400 µg of misoprostol were studied. 
Methods: Women undergoing termination of pregnancy by suction evacuation were randomized to 
receive 400 μg of sublingual or vaginal misoprostol every 3 hours for 5 doses. Venous blood 
samplings were taken at 180, 200, 240, 360, 380, 420, 540, 560, 600, 720, 740, 780 and 900 
minutes after the first dose of misoprostol. Misoprostol acid (MPA) was determined in plasma 
samples using gas chromatography/tandem mass spectrometry.  
Results: The peak plasma levels of MPA decreased with successive doses of vaginal misoprostol, 
whereas the peak plasma levels were similar with successive doses of sublingual misoprostol. The 
peak plasma levels of MPA after sublingual misoprostol were significantly higher than those after 
vaginal administration after the third dose. As a result, the area under the MPA concentration-time 
curve after sublingual administration became significantly higher than that after vaginal 
misoprostol after the final dose (p<0.031). However, subgroup analysis in the vaginal 
administration group showed that the progressive decline in the peak plasma levels of MPA 
occurred only in women with significant vaginal bleeding.  
Conclusion: The peak plasma level of MPA after each dose of misoprostol is higher and the 
bioavailability is also greater after sublingual administration of repeated doses of misoprostol when 
compared to those after vaginal administration. The difference was probably due to the reduction in 
absorption of vaginal misoprostol in the presence of significant vaginal bleeding.  
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Introduction: 
 
Misoprostol is widely used in obstetrics and gynaecology for medical abortion, cervical priming 
and induction of labour (El-Refaey et al, 1995; Ho et al, 1997; WHO, 1993; Ashok et al, 1998; 
Ngai et al, 1995; Ngai et al, 1996; El-Refaey et al, 1994). Although misoprostol is originally 
developed for oral administration for the management of peptic ulcer, it was commonly used 
vaginally for medical abortion, cervical priming and labour management in obstetrics and 
gynaecology. Recently, it was found that misoprostol can be used sublingually as well. A 
pharmacokinetic study has compared the absorption kinetics of misoprostol after vaginal or 
sublingual administration of a single dose of misoprostol. It was shown that after sublingual 
administration of misoprostol, the time for misoprostol acid (MPA), the active metabolite of 
misoprostol, to reach peak concentration was significantly shorter, while the peak plasma 
concentration and the bioavailability (as measured by the area under the time-concentration curve 
of MPA) of MPA were significantly higher than those after vaginal administration. However, the 
plasma level of MPA was sustained for a longer time after vaginal administration. The plasma  
level of MPA dropped to a negligible level 4 hours after sublingual administration, but the plasma 
level was still maintained at the end of 6 hours after vaginal administration (Tang et al, 2002). A 
number of clinical studies have demonstrated the effectiveness of sublingual administration of 
misoprostol (Tang et al, 2003; Tang et al, 2004). However, in certain applications like second 
trimester medical abortion, the efficacy of the vaginal route is superior to that of the sublingual 
route despite the more favourable pharmacokinetic profile (Tang et al, 2004). This may be due to 
the fact that in second trimester medical abortion, repeated doses are often required and the 
pharmacokinetic profile of repeated administration may be different from that after a single dose. 
Knowing the pharmacokinetic properties of the drug after repeated doses is important for designing 
an effective and safe regimen for different clinical indications. Therefore, in this study, we 
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compared the pharmacokinetics of misoprostol after vaginal or sublingual administration of 
repeated doses of misoprostol.  
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Materials and methods 
 
Twenty pregnant women requesting termination of pregnancy at a gestation of less than 12 weeks 
were recruited into the study. These 20 women were recruited from women requesting surgical 
termination of pregnancy. The study was approved by the Institutional Review Board of the 
University of Hong Kong / Hospital Authority Hong Kong West Cluster. Inclusion criteria were 
healthy women who were pregnant for less than 12 weeks. Women with a history of allergy to 
misoprostol and major medical problems were excluded. The subjects were asked to keep fasted 
overnight and were admitted to the hospital on the morning one day before the operation. They 
were randomized into 2 groups to receive 400 µg of misoprostol every 3 hours for 5 doses either 
sublingually or vaginally. The randomization schedule was generated by computer and the 
allocations were put in opaque sealed envelops.  Sublingual misoprostol was given by putting 2 
tablets of misoprotol under the tongue and allowing them to dissolve spontaneously. For vaginal 
misoprostol, two tablets of the drug were inserted into the posterior fornix of the vagina by one of 
the investigators. Venous blood samples (10 ml) were drawn over the next 15 hours at 180, 200, 
240, 360, 380, 420, 540, 560, 600, 720, 740, 780 and 900 minutes after the administration of 
misoprostol. The time intervals were chosen according to our previous pharmacokinetic study 
which showed that the peak concentration was reached after a median of 20 and 60 minutes for 
sublingual and vaginal administration respectively (Tang et al 2002). We did not collect blood 
samples in the first 180 minutes because the data were already available in our previous study 
(Tang et al 2002). Surgical termination of pregnancy with vacuum aspiration was performed for 
these subjects if there was an on-going pregnancy or incomplete abortion upon completion of the 5 
doses of misoprostol.  The blood samples were centrifuged to obtain the plasma and frozen in 
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liquid nitrogen immediately. The samples were then stored at below –20ºC and were sent to 
Department of Pediatrics, Philipps University Marburg for analysis. MPA was determined in the 
plasma samples using gas chromatography/tandem mass spectrometry (GC/MS/MS). After addition 
of 15(S)-15-methyl prostaglandin E
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2 (15-methyl-PGE2) as internal standard, MPA was extracted 
from both matrices using a reversed phase cartridge. The prostanoids were derivatized with O-
2,3,4,5,6-pentafluorobenzylhydroxylamine hydrochloride (PFBHA) and 2,3,4,5,6-
pentafluorobenzylbromide (PFBB) to the pentafluorobenzyl oxime (PFBO)-pentafluorobenzyl ester 
(PFB) derivatives.  The sample was applied to TLC with ethylacetate/hexane 1:1 (v/v) as the 
developing solvent. The corresponding zone was extracted. After derivatization to the 
trimethylsilylether, MPA was determined by GC/MS/MS using the [M-pentafluorobenzyl]--ions as 
precursor in the negative ion chemical ionization mode. The product ions used for quantification 
were [P - 2TMSOH - C6F5CH2OH]- (MPA) and [P - 2TMSOH - C6F5CH2OH - CO2]- (15-methyl-
PGE2), respectively. The detection limit of the assay is 1 pg/sample. 
The primary outcome measures of the study were the area under the curve of plasma 
concentrations of MPA against time from 180 to 900 minutes (AUC180-900). The area under the 
time-concentration curve was calculated by the trapezoidal method. The area under the time-
concentration curve was divided into trapezium segments according to the time intervals of blood 
sampling. The area of each segment was computed according to the following formula for 
calculation of trapezium area: 0.5 [Cx + C x-1] [time interval], x = 1 to 12 (x is the order of the blood 
samplings). The AUC180-900 was calculated by summating the 12 trapezium segments. No similar 
study was found in the literature on the pharmacokinetics of repeated doses of sublingual or vaginal 
misoprostol. According to a previous pharmacokinetic study on a single dose of misoprostol, 10 
subjects in each arm will have 80% power in detecting a 50% difference in bioavailability at 5% 
significance level. 
  SPSS 11 for window statistical package was used for data analysis. Continuous variables 
were compared by Student t test if the data were normally distributed. Kruskal-Wallis test or Mann-
 6
Whitney test was used if the data were skewed. P value (two-tailed) of <0.05 was taken as 
statistically significant. 
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Results 
 
The age, gestational age and body surface area of the 2 groups are listed in Table 1. There was no 
statistically significant difference between the 2 groups in these demographic characteristics. The 
mean plasma concentrations of MPA after administration of 400 µg misoprostol every 3 hours for 5 
doses by sublingual and vaginal routes are shown in Figure 1. The peak plasma levels of MPA 
decreased with successive doses of vaginal misoprostol, whereas the peak plasma levels were 
similar with successive doses of sublingual misoprostol. The peak plasma levels after sublingual 
misoprostol were significantly higher than those after vaginal administration after the third dose. As 
a result, the area under the curve after sublingual administration became significantly higher than 
that after vaginal administration after the final dose (p<0.031) (Table 2 and Fig. 2).  
 As the majority of women developed vaginal bleeding after administration of misoprostol, 
this might adversely affect the absorption of misoprostol given vaginally. We suspected that this 
might account for the progressive decline of the plasma levels of MPA after vaginal administration. 
In the vaginal administration group in this study, eight women developed vaginal bleeding and 
subsequently aborted while two women had no vaginal bleeding.  Therefore, we compared the 
pharmacokinetics of misoprostol in these two subgroups of women in the vaginal administration 
group. The plasma concentrations of MPA in these two subgroups of women are shown in Figure 3 
while the areas under the MPA time-concentration curves are shown in Figure 4. It can be seen in 
the subgroup with vaginal bleeding, there was a progressive decline in the peak plasma 
concentrations of MPA with repeated doses of vaginal misoprostol while in the subgroup with no 
vaginal bleeding, there was no progressive decline in the peak plasma concentrations of MPA with 
repeated doses. The plasma concentrations of MPA in the subgroup with significant amount of 
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vaginal bleeding and abortion were significantly lower than the subgroup without vaginal bleeding 
at 540 minutes (p<0.05), 560 minutes (p<0.05), 600 minutes (p<0.05), 720 minutes (p<0.05), 740 
minutes (p<0.05) and 740 minutes (p<0.05). Because of the progressive decline in the peak plasma 
concentrations of MPA after vaginal administration of repeated doses of misoprostol in the vaginal 
bleeding group, the areas under the time-concentration curve of MPA in this subgroup were 
significantly lower than those in the subgroup with no vaginal bleeding at 720 minutes (p<0.05) 
and 740 minutes (p<0.05). In the group of women given misoprostol sublingually, the plasma 
concentrations of MPA were comparable in the two subgroups of women with or without vaginal 
bleeding (data not shown). The plasma concentrations of MPA in the two subgroups of women 
given misoprosstol vaginally were also compared with those in the sublingual group. The plasma 
concentrations of MPA in the subgroup of women with vaginal bleeding after vaginal 
administration of misoprostol were significantly  lower than those after sublingual administration 
(whole group) at 420 minutes (p<0.01), 560 minutes (p<0.001), 600 minutes (p<0.001), 720 
minutes (p<0.001), 740 minutes (p<0.001), 780 minutes (p<0.001) and 900 minutes (p<0.001). The 
areas under the time-concentrations curves of MPA in this subgroup were also significantly lower 
than those in the sublingual group at 720 minutes (p<0.05), 740 minutes (p<0.05), 780 minutes 
(p<0.05) and 900 minutes (p<0.01). On the other hand, the plasma concentrations of MPA in the 
subgroup of women without vaginal bleeding after vaginal administration of misoprostol were 
significantly higher than those in the sublingual group (whole group with and without vaginal 
bleeding) at 360 minutes (p<0.05), 540 minutes (p<0.05) and 90 minutes (p<0.05). Although the 
areas under the time-concentration curves of MPA in this subgroup without vaginal bleeding after 
vaginal administration of misoprostol were all higher than those in the sublingual group, the 
differences were not statistically significant, probably because of the small sample size in this 
subgroup.  
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This is the first study on the pharmacokinetics of MPA after vaginal or sublingual administration of 
repeated doses of misoprostol. According to the previous studies, the peak plasma concentration 
and bioavailability after a single dose of misoprostol are higher after sublingual administration than 
those after vaginal administration (Tang et al, 2002, Aronsson et al, 2007). However, the plasma 
level of MPA after a single dose of vaginal misoprostol is sustained for a longer time than that after 
sublingual misoprostol. Despite a rapid rise of plasma level of MPA after sublingual administration, 
the plasma level of MPA dropped more rapidly than that after vaginal administration so that after 3 
hours the plasma level is lower than that after vaginal administration. This may be attributed to the 
continuous absorption of misoprostol from the vaginal mucosa over the few hours after its 
administration. There is still a measurable amount of MPA in the blood at 6 hours after vaginal 
administration (Aronsson et al, 2007). Therefore, it is expected that with repeated vaginal 
administration at an interval of less than 6 hours, the MPA may accumulate in the plasma and reach 
a level consistently higher than that after sublingual administration of misoprostol so that the total 
area under the time-concentration curve, an indication of the bioavailability, will also be higher. 
However, the results of this study do not appear to be consistent with this hypothesis. The peak 
plasma level after successive doses of vaginal misoprostol actually becomes lower and lower. As a 
result the total bioavailability of the drug at the end of the study at 900 minutes is actually higher 
for sublingual misoprostol. It seems that there is no accumulation of MPA after repeated vaginal 
administration of misoprostol. The present pharmacokinetic study has shown that the absorption of 
vaginal misoprostol actually became less efficient with time. We postulate that this may be due to 
the presence of vaginal bleeding with the onset of the abortion process. The vaginal bleeding may 
interfere with the absorption of misoprostol. It may also wash away some misoprostol tablets 
inserted vaginally.  
To test our hypothesis, we compared the pharmacokinetics of MPA after vaginal 
administration of misoprostol in the eight women with significant vaginal bleeding with those in 
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the two women with no vaginal bleeding. The results in the two subgroups of women in the vaginal 
administration group show that the progressive decline in the peak plasma concentrations of MPA 
occurred only in the subgroup with significant vaginal bleeding. In the vaginal subgroup without 
vaginal bleeding, the plasma concentrations of MPA were significantly higher than those in the 
sublingual group at several time points, usually about 180 minutes after the misoprostol 
administration. The areas under the time-concentration curves in this subgroup were also higher 
than those in the sublingual group though the differences were not statistically significant. In the 
sublingual administration group, the presence of significant vaginal bleeding did not affect the 
pharmacokinetics of misoprostol. These data support our hypothesis that the vaginal bleeding can 
adversely affect the absorption of misoprostol in the vagina. They also support our original 
hypothesis that in the absence of vaginal bleeding, vaginal administration of repeated doses of 
misoprostol will lead to accumulation of MPA in the plasma leading to higher plasma 
concentrations and possibly also higher areas under the time-concentration curves of MPA. 
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The results in this study appear to be inconsistent with the findings of a clinical trial (Tang 
et al 2004) comparing vaginal misoprostol with sublingual misoprostol in termination of second 
trimester pregnancies. In this clinical trial, the regimens were similar to those in this 
pharmacokinetic study with 400μg of misoprostol given every 3 hours for 5 doses in both the 
vaginal and the sublingual administration groups. It was found that the success rate for second 
trimester abortion for vaginal misoprostol was 85% which was higher than that of sublingual 
misoprostol (64%). However, the outcome of treatment in those with vaginal administration of 
misoprostol in the presence of heavy vaginal bleeding may not be affected by the reduced 
absorption of misoprostol as those patients with the heaviest vaginal bleeding are usually aborting 
and they may not require high plasma levels of MPA. Moreover, although it is logical to presume 
that a higher plasma level is associated with a more potent clinical effect, the plasma thresholds for 
various clinical actions have never been established. A very low and sustained plasma level may 
already be adequate for many of the clinical actions. Regular uterine contractions have been 
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demonstrated for vaginal misoprostol up to 4 hours despite a low plasma level of MPA (Aronsson 
et al 2004). In addition, the local cervical priming effect of vaginal misoprostol should not be 
overlooked. A direct vagina-to-uterus transport described for progesterone absorption may also 
exist for misoprostol absorption and can explain the more favourable clinical effects with vaginal 
administration when compared with sublingual administration despite a more favourable 
bioavailability of the latter (Cicinelli et al, 2000; Cicinelli et al, 2000).  
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On the other hand, vaginal administration of misoprostol may not be appropriate in the 
prophylaxis or management of postpartum haemorrhage. In this situation, a rapid rise in the plasma 
concentration of MPA may be needed for its clinical action.  Moreover the presence of bleeding 
after delivery may affect the absorption of vaginal misoprostol. 
 In conclusion, the peak plasma level of MPA after each dose of misoprostol is higher and 
the bioavailability is also greater after sublingual administration of misoprostol than those after 
vaginal administration. This difference is likely to be due to the adverse effect of heavy vaginal 
bleeding on the absorption of misoprostol given vaginally.  However, a better bioavailability does 
not necessarily mean a better clinical effect in medical abortion because other factors may affect 
the efficacy of the drug.  
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Table 1 Demographic characteristics of the 20 subjects (SD) 1 
 Sublingual  
(n=10) 
Vaginal 
(n=10) 
P value 
Mean age/ years 
 
31.7 (8.3) 29.8 (7.7) 0.704 
Mean gestational 
age/days 
59.9 (14.2) 54.8 (14.2) 0.283 
Mean weight/kg 
 
52.1 (9.9) 51.2 (4.0) 0.544 
Mean height/cm 
 
158.1 (6.5) 159.3 (4.1) 0.849 
Mean Body 
surface area/m2
1.51 (0.16) 1.50 (0.06) 0.326 
a   2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
b   
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Table 2 Pharmacokinetic parameters of the 2 routes of administration of misoprostol  1 
 Sublingual  
(n=10) 
Vaginal 
(n=10) 
P value 
Plasma level at 180 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 180 
minutes (AUC180)/ pg · hr/mL* 
Mean(SD) 
Median 
 
 
 
 123.1 ± 119.5 
(86.8) 
 
 
 
 184.7 ± 179.3 
(130.2) 
 
 
 202.2 ± 143.2 
(171.5) 
 
 
 
 303.4 ± 214.9 
(257.3) 
 
 
0.096 
 
 
 
 
0.096 
Plasma level at 200 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 200 
minutes (AUC200)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 380.0 ± 239.2 
(257.0) 
 
 
 
 268.6 ± 233.3 
(229.8) 
 
 
 438.2 ± 293.3 
(394.5) 
 
 
 
 410.1 ± 272.2 
(349.5) 
 
 
0.597 
 
 
 
 
0.131 
Plasma level at 240 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 240 
minutes (AUC240)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 489.5 ± 213.6 
(423.5) 
 
 
 
 558.4 ± 360.8 
(486.5) 
 
 
 395.1 ± 247.6 
(429.0) 
 
 
 
 687.9 ± 426.6 
(641.6) 
 
 
0.406 
 
 
 
 
0.326 
Plasma level at 360 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 360 
minutes (AUC360)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 100.5 ± 68.8 
(74.1) 
 
 
 
 1148.4 ± 611.6 
(938.0) 
 
 
 209.9 ± 174.3 
(215.0) 
 
 
 
 1292.8 ± 821.1 
(1274.6) 
 
 
0.226 
 
 
 
 
0.545 
Plasma level at 380 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 380 
 
 
 331.4 ± 281.3 
(251.0) 
 
 
 
 
 369.2 ± 288.1 
(382.0) 
 
 
 
 
0.597 
 
 
 
 15
minutes (AUC380)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 1220.4 ± 665.5 
(977.7) 
 
 1389.4 ± 883.0 
(1376.5) 
 
0.496 
Plasma level at 420 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 420 
minutes (AUC420)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 610.5 ± 402.0 
(481.0) 
 
 
 
 1534.3 ± 840.0 
(1188.9) 
 
 
 255.3 ± 212.7 
(239.0) 
 
 
 
 1597.5 ± 1009.0 
(1570.6) 
 
 
0.041 
 
 
 
 
0.650 
Plasma level at 540 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 540 
minutes (AUC540)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 91.5 ± 37.2 
(93.3) 
 
 
 
 2236.3 ± 1170.9 
 (1792.2) 
 
 
 127.3 ± 150.8 
(54.2) 
 
 
 
 1980.2 ± 1289.4 
 (1808.3) 
 
 
0.406 
 
 
 
 
0.821 
Plasma level at 560 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 560 
minutes (AUC560)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 429.6 ± 164.1 
(514.5) 
 
 
 
 2323.1 ± 1186.1 
 (1882.0) 
 
 
 212.4 ± 209.7 
(145.0) 
 
 
 
 2036.8 ± 1333.9 
 (1838.4) 
 
 
0.028 
 
 
 
 
0.762 
Plasma level at 600 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 600 
minutes (AUC600)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 568.3 ± 307.6 
(590.0) 
 
 
 
 2655.8 ± 1292.9 
 (2179.7) 
 
 
 215.2 ± 257.7 
(121.0) 
 
 
 
 2179.3 ± 1444.2 
 (1910.7) 
 
 
0.007 
 
 
 
 
0.450 
Plasma level at 720 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 720 
minutes (AUC720)/ pg · hr/mL 
Mean(SD) 
 
 
 107.7 ± 39.3 
(120.0) 
 
 
 
 3331.8 ± 1570.1 
 
 
 101.9 ± 163.0 
(25.1) 
 
 
 
 2496.4 ± 1762.8 
 
 
0.023 
 
 
 
 
0.226 
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Median 
 
 (3037.3)  (2034.0) 
Plasma level at 740 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 740 
minutes (AUC740)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 483.1 ± 234.4 
(436.0) 
 
 
 
 3430.3 ± 1600.8 
 (3115.6) 
 
 
 188.5 ± 141.5 
(150.0) 
 
 
 
 2544.7 ± 1799.9 
 (2057.6) 
 
 
0.002 
 
 
 
 
0.226 
Plasma level at 780 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 780 
minutes (AUC780)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 323.8 ± 154.0 
(276.0) 
 
 
 
 3699.2 ± 1674.3 
 (3353.1) 
 
 
 157.9 ± 173.8 
(85.0) 
 
 
 
 2433.7 ± 1829.4 
 (2013.3) 
 
 
0.007 
 
 
 
 
0.072 
Plasma level at 900 minutes/ 
pg/mL 
Mean(SD) 
Median 
 
Area under the curve to 900 
minutes (AUC900)/ pg · hr/mL 
Mean(SD) 
Median 
 
 
 
 98.9 ± 71.3 
(81.0) 
 
 
 
 4342.6 ± 1723.3 
 (4032.0) 
 
 
 101.2 ± 154.5 
(27.6) 
 
 
 
 2655.9 ± 2056.4 
 (2107.0) 
 
 
0.060 
 
 
 
 
0.031 
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Figure 1 Plasma concentrations of misoprostol acid after vaginal and sublingual administration of 
repeated doses of misoprostol 
 
Figure 2 Areas under the time-concentration curves of plasma misoprostol acid in the vaginal and 
sublingual groups 
 
Figure 3 Plasma concentrations of misoprostol acid in the sublingual group and the two subgroups 
of women in the vaginal group: (a) with vaginal bleeding and (b) without vaginal bleeding 
 
Figure 4 Areas under the time-concentration curves of plasma misoprostol acid in the two 
subgroups of women in the vaginal group: (a) with vaginal bleeding and (b) without vaginal 
bleeding. 
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Figure 4 
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